IGC Pharma (IGC) Non-Current Assets (2011 - 2026)

IGC Pharma (IGC) has 16 years of Non-Current Assets data on file, last reported at $8.0 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $8.0 million, up 37.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 37.38% YoY), and the FY2026 annual result was $8.0 million, up 37.38% from the prior year.
• Non-Current Assets advanced to $8.0 million in Q1 2026 per IGC's latest filing, from $7.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $11.7 million in Q1 2022 and troughed at $5.8 million in Q2 2025.
• A 5-year average of $8.5 million and a median of $7.9 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2026: Non-Current Assets slumped 42.15% in 2024, then surged 37.38% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $10.7 million in 2022, then decreased by 28.37% to $7.7 million in 2023, then slipped by 21.48% to $6.0 million in 2024, then soared by 31.44% to $7.9 million in 2025, then rose by 1.46% to $8.0 million in 2026.
• Business Quant data shows IGC's Non-Current Assets at $8.0 million in Q1 2026, $7.9 million in Q4 2025, and $7.7 million in Q3 2025.